• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期肺癌中表达程序性死亡-1和细胞毒性T细胞抗原-4的T细胞免疫表型:局部与全身免疫反应

Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response.

作者信息

Kwiecien Iwona, Skirecki Tomasz, Polubiec-Kownacka Małgorzata, Raniszewska Agata, Domagala-Kulawik Joanna

机构信息

Department of Internal Medicine and Hematology Laboratory of Flow Cytometry, Military Medical Institute, Warsaw, ul. Szaserow 128, 04-141 Warsaw, Poland.

Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, ul. Marymoncka 99/103, 01-813 Warsaw, Poland.

出版信息

Cancers (Basel). 2019 Apr 21;11(4):567. doi: 10.3390/cancers11040567.

DOI:10.3390/cancers11040567
PMID:31010080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6520959/
Abstract

The overexpression of programmed death-1 (PD-1) and cytotoxic T cell antigen 4 (CTLA-4) receptors on T cells are among the major mechanisms of tumor immunoevasion. However, the expression pattern of these receptors on T cell subpopulations of a different activation status and at different sites is poorly characterized. Thus, we analyzed the expression of PD-1 and CTLA-4 on the naïve, activated, memory, and activated memory T cells. Bronchoalveolar lavage fluid (BALF) from the lung affected by lung cancer (clBALF), the opposite 'healthy' lung (hlBALF), and peripheral blood (PB) samples were collected from 32 patients. The cells were analyzed by multiparameter flow cytometry. The proportion of memory, activated, and activated memory CD8+ cells with the expression of PD-1 and CTLA-4 were elevated in the clBALF when compared to the hlBALF (insignificantly), but these proportions were significantly higher in the BALF when compared with the PB. The proportions of PD-1+ and CTLA-4+ T cells were elevated in the squamous cell carcinoma when compared to the adenocarcinoma patients. Also, the expression of PD-1 and CTLA-4 on T cells from the BALF was significantly higher than from PB. We report for the first time the differential expression of checkpoint molecules on CD4+ and CD8+ lymphocytes at a different stage of activation in the local environment of lung cancer. Moreover, the circulating T cells have a distinct expression of these receptors, which suggests their poor utility as biomarkers for immunotherapy.

摘要

程序性死亡-1(PD-1)和细胞毒性T细胞抗原4(CTLA-4)受体在T细胞上的过表达是肿瘤免疫逃逸的主要机制之一。然而,这些受体在不同激活状态和不同部位的T细胞亚群上的表达模式却鲜有描述。因此,我们分析了PD-1和CTLA-4在初始、活化、记忆和活化记忆T细胞上的表达情况。收集了32例患者受肺癌影响的肺组织的支气管肺泡灌洗液(clBALF)、对侧“健康”肺组织的支气管肺泡灌洗液(hlBALF)以及外周血(PB)样本。通过多参数流式细胞术对细胞进行分析。与hlBALF相比,clBALF中表达PD-1和CTLA-4的记忆、活化和活化记忆CD8+细胞比例升高(不显著),但与PB相比,这些比例在BALF中显著更高。与腺癌患者相比,鳞状细胞癌患者中PD-1+和CTLA-4+ T细胞的比例升高。此外,BALF中T细胞上PD-1和CTLA-4的表达显著高于PB中的T细胞。我们首次报道了在肺癌局部环境中不同激活阶段CD4+和CD8+淋巴细胞上检查点分子的差异表达。此外,循环T细胞对这些受体有独特的表达,这表明它们作为免疫治疗生物标志物的效用不佳。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/e31e11535314/cancers-11-00567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/c74fab7cf6a2/cancers-11-00567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/d1478993bd82/cancers-11-00567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/e31e11535314/cancers-11-00567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/c74fab7cf6a2/cancers-11-00567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/d1478993bd82/cancers-11-00567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7526/6520959/e31e11535314/cancers-11-00567-g003.jpg

相似文献

1
Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response.早期肺癌中表达程序性死亡-1和细胞毒性T细胞抗原-4的T细胞免疫表型:局部与全身免疫反应
Cancers (Basel). 2019 Apr 21;11(4):567. doi: 10.3390/cancers11040567.
2
Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans.人类肺癌微环境中调节性T细胞、CTLA-4表面和细胞内表达以及白细胞介素-17水平升高。
Cancer Immunol Immunother. 2017 Feb;66(2):161-170. doi: 10.1007/s00262-016-1930-6. Epub 2016 Nov 19.
3
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry.程序性死亡受体1(PD-1)配体的鉴定:通过流式细胞术检测肺癌环境中巨噬细胞上的程序性死亡配体1(PD-L1)和程序性死亡配体2(PD-L2)
Transl Lung Cancer Res. 2021 Apr;10(4):1679-1689. doi: 10.21037/tlcr-20-1103.
4
[Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].[CTLA-4、PD-1和PD-L1在小细胞肺癌患者外周血中的分布及临床意义]
Zhongguo Fei Ai Za Zhi. 2017 Nov 20;20(11):755-760. doi: 10.3779/j.issn.1009-3419.2017.11.06.
5
Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.阻断外周血 CD8+T 细胞 CTLA-4 的表达可增强膀胱癌的抗肿瘤疗效。
Cancer Chemother Pharmacol. 2019 May;83(5):911-920. doi: 10.1007/s00280-019-03800-x. Epub 2019 Mar 8.
6
Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.在神经周围鳞状细胞癌患者的肿瘤内,表达 PD-1、CTLA-4 和 Tim-3 的 CD8 T 细胞频率升高。
PLoS One. 2017 Apr 19;12(4):e0175755. doi: 10.1371/journal.pone.0175755. eCollection 2017.
7
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
8
[Deep lung--cellular reaction to HIV].[深部肺脏——对HIV的细胞反应]
Rev Port Pneumol. 2007 Mar-Apr;13(2):175-212.
9
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.联合抗 CTLA-4 加抗 PD-1 检查点阻断利用了与单药治疗部分不同的细胞机制。
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709. doi: 10.1073/pnas.1821218116. Epub 2019 Oct 21.
10
[Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].CD4⁺T细胞上共抑制分子CTLA-4、LAG-3、PD-1和CD39的表达水平与非小细胞肺癌的进展相关
Zhonghua Zhong Liu Za Zhi. 2014 Jun;36(6):424-9.

引用本文的文献

1
Imbalance of B-Cell Subpopulations in the Microenvironment of Sarcoidosis or Lung Cancer.肉芽肿病或肺癌微环境中 B 细胞亚群失衡。
Cells. 2024 Jul 29;13(15):1274. doi: 10.3390/cells13151274.
2
Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer.支气管肺泡灌洗液评估有助于肺癌的精准医疗。
Cancer Biol Med. 2023 Dec 29;21(3):230-51. doi: 10.20892/j.issn.2095-3941.2023.0381.
3
Flow Cytometric Analysis of Macrophages and Cytokines Profile in the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer.

本文引用的文献

1
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.非小细胞肺癌中的免疫检查点抑制剂——走向日常临床应用
Adv Respir Med. 2018;86(3). doi: 10.5603/ARM.2018.0022.
2
Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates.在人类肿瘤浸润物中,旁观者 CD8 T 细胞丰富且表型独特。
Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.
3
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.新辅助 PD-1 阻断治疗可切除性肺癌。
肺癌患者支气管肺泡灌洗液体中巨噬细胞的流式细胞术分析及细胞因子谱
Cancers (Basel). 2023 Oct 27;15(21):5175. doi: 10.3390/cancers15215175.
4
Immune-check blocking combination multiple cytokines shown curative potential in mice tumor model.免疫检查点阻断联合多种细胞因子在小鼠肿瘤模型中显示出治疗潜力。
Cancer Med. 2023 Jun;12(12):13573-13585. doi: 10.1002/cam4.6053. Epub 2023 May 18.
5
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer.比较晚期肺癌患者支气管肺泡灌洗液(BAL)和外周血中的 T 细胞亚群。
Cells. 2022 Oct 14;11(20):3226. doi: 10.3390/cells11203226.
6
Effector Memory T Cells and CD45RO+ Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients.肺癌患者转移性与非转移性淋巴结中的效应记忆 T 细胞和 CD45RO+调节性 T 细胞。
Front Immunol. 2022 May 2;13:864497. doi: 10.3389/fimmu.2022.864497. eCollection 2022.
7
Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.肺癌患者淋巴结抽吸物中 PD-1+、PDL-1+和 CD80+树突状细胞的免疫抑制特性。
Cancer Immunol Immunother. 2022 Oct;71(10):2469-2483. doi: 10.1007/s00262-022-03178-5. Epub 2022 Mar 7.
8
Lung Cancer Stem Cells-Origin, Diagnostic Techniques and Perspective for Therapies.肺癌干细胞——起源、诊断技术及治疗前景
Cancers (Basel). 2021 Jun 15;13(12):2996. doi: 10.3390/cancers13122996.
9
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry.程序性死亡受体1(PD-1)配体的鉴定:通过流式细胞术检测肺癌环境中巨噬细胞上的程序性死亡配体1(PD-L1)和程序性死亡配体2(PD-L2)
Transl Lung Cancer Res. 2021 Apr;10(4):1679-1689. doi: 10.21037/tlcr-20-1103.
10
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.寻找与间皮瘤中程序性死亡受体配体1(PD-L1)阻断联合使用的有趣伙伴:聚焦于T细胞免疫球蛋白和粘蛋白结构域分子3(TIM-3)和淋巴细胞激活基因3(LAG-3)。
Cancers (Basel). 2021 Jan 14;13(2):282. doi: 10.3390/cancers13020282.
N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.
4
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
5
Understanding Subset Diversity in T Cell Memory.理解 T 细胞记忆中的亚群多样性。
Immunity. 2018 Feb 20;48(2):214-226. doi: 10.1016/j.immuni.2018.02.010.
6
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.免疫疗法:胸恶性肿瘤的新标准?胸肿瘤学大会欧洲呼吸学会研究研讨会综述。
Eur Respir J. 2018 Feb 14;51(2). doi: 10.1183/13993003.02072-2017. Print 2018 Feb.
7
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.对PD-1和PD-L1阻断的耐药机制。
Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303.
8
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.纳武利尤单抗治疗晚期非小细胞肺癌的有效性和安全性:真实世界数据。
Lung Cancer. 2018 Dec;126:217-223. doi: 10.1016/j.lungcan.2017.11.015. Epub 2017 Nov 23.
9
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.非小细胞肺癌患者外周血T细胞中PD-1/PD-L1和PD-L2的表达
Oncotarget. 2017 Oct 24;8(60):101994-102005. doi: 10.18632/oncotarget.22025. eCollection 2017 Nov 24.
10
How to evaluate the immune status of lung cancer patients before immunotherapy.如何在免疫治疗前评估肺癌患者的免疫状态。
Breathe (Sheff). 2017 Dec;13(4):291-296. doi: 10.1183/20734735.001917.